US20070179424A1 - High concentration white cells, a method for agglomeration of the high concentration and a bag set for use in conjunction therewith - Google Patents
High concentration white cells, a method for agglomeration of the high concentration and a bag set for use in conjunction therewith Download PDFInfo
- Publication number
- US20070179424A1 US20070179424A1 US11/640,138 US64013806A US2007179424A1 US 20070179424 A1 US20070179424 A1 US 20070179424A1 US 64013806 A US64013806 A US 64013806A US 2007179424 A1 US2007179424 A1 US 2007179424A1
- Authority
- US
- United States
- Prior art keywords
- blood
- therapeutic product
- bag
- white
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0236—Mechanical aspects
- A01N1/0263—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving, e.g. cool boxes, blood bags or "straws" for cryopreservation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
- A61M1/0236—Multiple bag systems for separating or storing blood components with sampling means, e.g. sample bag or sampling port
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0272—Apparatus for treatment of blood or blood constituents prior to or for conservation, e.g. freezing, drying or centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0281—Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
- A61J1/12—Bag-type containers with means for holding samples of contents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0439—White blood cells; Leucocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0462—Placental blood, umbilical cord blood
Definitions
- the following invention is directed generally to the therapeutic utilization of white blood cells, a technique for sequestering the white blood cells by causing them to coalesce in a population density greater than they normally occur in nature, and a method for causing an enriched concentration in conjunction with an array of bags oriented in a set that facilitates both the concentration process and a method for preserving the white blood cells.
- PB placenta/umbilical cord blood
- PB contains large numbers of hematopoietic stem and progenitor cells that endow PB with extraordinary therapeutic capabilities in the reconstitution of bone marrow damaged as a result of inherited diseases, accidents or medical procedures.
- PB contains immune cells potentially capable of mounting specific responses against the recipients of such transplants, but in contrast to adult immunological cells, those in PB display a lower, perhaps much lower tendency to produce damaging immune responses against the recipient.
- the clinical syndrome produced by the immuno responses of the graft against the recipient's cells and tissues is designated “Graft versus Host Disease” (GVHD).
- the recipient's own immune response against the graft is abrogated by drugs and irradiation treatments designed to reduce or eliminate the immunological and other hematopoietic cells and thus avoid the host versus graft immune reaction that would cause rejection of the graft.
- the principal targets of these Graft versus Host and Host versus Graft immune reactions are antigens encoded by the genes of the HLA (Human Leukocyte Antigen) system and that successful outcomes of bone marrow transplants are dependent on the sharing of HLA antigens by donor and recipient.
- Sibling donors who have inherited the same paternal and maternal HLA genes present in the recipient are HLA-identical and thus, optimal from this viewpoint.
- HLA-identical sibling donors Patients lacking such HLA-identical sibling donors must receive transplants from more distant relatives or from unrelated donors. Because the HLA system includes several discrete genes each of which displays an extremely large number of antigenically different variants in the population, such distant relative-donor or unrelated-donor transplants must be expected to contain a variable number of HLA incompatibilities unless they are selected from among potential donors by identifying the specific variants present in each and choosing donors whose HLA antigens match those of the recipient. To perform this selection with significant probability of success, it is necessary to have access to large panels of potential donors whose HLA antigens are known. In the case of unrelated donor PB, this requires establishing a bank of frozen HLA-typed units collected from random placentas.
- cryopreservative solution a cryopreservative solution
- the volume of each cryopreserved unit becomes very large and that a relatively large amount of possibly deleterious cryopreservative is eventually administered to the recipients of such PB units.
- Administration of crybprotectant and hemoglobin from erythrocytes destroyed by using a freezing and thawing method designed to protect the stem and progenitor cells but not the erythrocytes may have toxic effects generally and especially on specific organs such as the kidney of the recipient.
- the therapeutic product of the present invention is advantageous, first, because it recovers all or almost all of the stem and progenitor cells of the original collection of PB in a small and uniform volume that requires minimal and predictable storage space, second, because it permits a consistent methodology for processing PB units which results in a routinely dependable product with less dependence on operator skill and third, because the potentially deleterious effects of the cryoprotectant and of the free hemoglobin are minimized.
- One first aspect to the nature of the product improved according to the present invention involves the methodology by which the white blood cells (which include the hematopoietic stem and progenitor cells) are separated from the bulk of other components in the whole PB and the manner in which the viability of such white cells is preserved by avoiding exposure to bacterial and fungal contamination, potentially damaging chemical agents, excessive centrifugal forces and osmotic imbalances.
- the white blood cells which include the hematopoietic stem and progenitor cells
- bacterial and/or fungal contamination occurs when PB or white blood cell suspensions derived from PB are exposed to ambient air in the course of preparatory manipulations; chemical damage is possible when certain chemicals are used to lyse the accompanying red blood cells or to aggregate white cells; and physical damage follows the use of excessive centrifugal speed in separation of the cellular components of the blood according to their density, by centrifugal stratification.
- the method according to the present invention provides for avoidance of prolonged exposure of the separated white blood cells to cryopreservation solutions at room temperature, an exposure that results in decreased viability of the white blood cells and of the stem and progenitor cells contained therein because of osmotic imbalances and, possibly, other toxic effects of the intracellular cryoprotectants themselves.
- Another aspect of the present invention involves the set of interconnected plastic containers (designated as bags).
- the set under the present invention permits a selective concentration of the white blood cells and of the stem and progenitor cells contained therein without reducing their normally high viability and freedom from contamination by infectious organisms from the environment.
- Whole PB is collected into a mother bag and is subsequently processed through a series of bags of appropriate chemical structure and physical shape and capacity culminating in storage of a separated fraction containing most of the white blood cells of the collected PB in liquid nitrogen at ⁇ 196 C inside a specially constructed freezer bag.
- Intervening steps include the addition of substances that enhance the aggregability of red blood cells and the separation of components by transferring supernatants into connected satellite bags.
- a special bag and its connecting assembly permits the addition of measured amounts of cryoprotectant to the separated white blood cell concentrate. This connecting assembly allows the cryoprotectant to be added to the white cells at a precise, slow speed required to maintain optimal cell viability.
- the bag which is to be used for freezing and storage includes a plurality of connected, but detachable compartments for sequestration of the white blood cells into different discrete chambers.
- One chamber, the main compartment is intended to keep the bulk of the white blood cells.
- a smaller compartment lends itself to the storage of a smaller fraction of the bag contents which may be separated from the main compartment without thawing, and extemporaneously detached from it for separate thawing and subsequent in vitro expansion of the hematopoietic stem and progenitor cell populations contained in the corresponding fraction of the white blood cells.
- a third and subsequent chamber contains very small aliquots of the white blood cell suspension and are intended to serve as detachable samples for testing the aptness of the unit to be transplanted or assessing its suitability as donor tissue for a specific recipient.
- the freezing bag also indudes indicia on the outer surface of each of its detachable areas for identification of the specific unit that will be stored in it, to facilitate storage and retrieval from designated sectors of cryogenic storage depots. Means are also provided in an exterior surface of the freezer bag to facilitate the placing and removing of the freezer bag into and from, respectively, its assigned storage location by automated instrumentation.
- the product becomes a bag containing a high concentration of white blood cells having a high degree of cell viability.
- a further object of the present invention is to provide a novel and useful method for generating the therapeutic product according to the previous object.
- a further object of the present invention is to provide an aseptic and interconnected bag set for use in conjunction with the method of developing the therapeutic product hereinabove.
- a further object of the present invention is to provide a freezer storage bag configured to contain the therapeutic dose in a cryoprotected environment for protracted periods of time until needed for dosage.
- a further object of the present invention is to provide a freezer bag as noted above provided with a plurality of compartments in which the therapeutic dose has been sequestered so that various aliquots can be strategically excised from the freezer bag for several purposes.
- a system for developing placental stem cells comprising in combination: a first blood bag adapted to receive blood from a placenta therewithin, means within the blood bag to prevent coagulation, reagent means removably coupled to the blood bag, means for separating supernatant from the first blood bag and into a white cell bag, means for separating white cells from plasma in the white cell bag, a plasma bag removably coupled to the white cell bag for receiving the expressed plasma from the white cell bag, cryoprotectant means operatively coupled to the white cell bag, and a stem cell freezing bag operatively coupled to the white cell bag for transferring contents from the white cell bag to the stem cell freezing bag.
- Coupling cryoprotectant means to the white cell bag, transferring contents from the white cell bag to a stem cell freezing bag, and freezing the stem cell freezing bag with its contents follows.
- FIG. 1 is a schematic view of the stem cell processing bag set according to the present invention.
- FIG. 2 is a detailed view of the freezing bag shown in FIG. 1 .
- FIG. 3 is a view similar to FIG. 2 showing the interior of the freezing bag.
- FIG. 4 is a flow chart the method according to the present invention.
- reference numeral 100 is directed to an apparatus according to the present invention.
- the apparatus 100 may be viewed as three arrays of bags collectively defining a bag set. Individual bags are provided with removable connection means to assure selected admission into the several bags only under aseptic conditions.
- the array of bags 100 includes six bags: a blood bag 10 defining a first array; a reagent bag 20 , a white cell bag 30 , a plasma bag 40 and a cryoprotectant bag 50 defining a second array; and a stem cell freezing bag 60 defining a third array.
- Cord blood i.e. blood from the placenta and umbilical cord
- the second array is connected to the blood bag 10 .
- a separation reagent is admitted to the blood bag via conduit 26 from reagent bag 20 .
- Centrifuging blood bag 10 follows. Supernatant containing the white blood cells is expressed off into the white cell bag 30 , whereupon further centrifugation takes place. Next, supernatant plasma is expressed off into the plasma bag 40 leaving sedimented white blood cells in white cell bag 30 .
- Cryoprotectant from the cryoprotectant bag 50 is transferred via conduit 59 to the white cell bag 30 slowly. Subsequently, the contents of the white cell bag 30 are transferred to the stem cell freezing bag 60 which is thereafter frozen and stored in liquid nitrogen for subsequent use.
- whole, placental, and umbilical cord blood is collected into a blood bag 10 provided with an anticoagulant such as Citrate, Phosphate and Dextrose (CPD).
- an anticoagulant such as Citrate, Phosphate and Dextrose (CPD).
- CPD Citrate, Phosphate and Dextrose
- cord blood will exhibit a ratio of one thousand (1,000) red cells to each “non-red” cell (for simplicity, assume the non-red blood cell can be labeled white blood cells).
- the main recognizable and functionally capable cells circulating in blood include erythrocytes, neutrophilic, eosinophilic, and basophilic granulocytes; B- T- and non B- non T-lymphocytes; monocytes and platelets.
- These mature cells derive from and are replaced, on demand, by morphologically recognizable dividing precursor cells for the respective lineages such as erythroblasts for the erythrocyte series, myeloblasts, promyelocytes and myelocytes for the granulocyte series, and megakaryocytes for the platelets.
- the precursor cells derive from more primitive cells that can simplistically be divided into two major subgroups: stem cells and progenitor cells.
- the blood bag 10 includes at least two access portals.
- a first portal 2 receives the cord blood whereupon the access portal 2 is sealed. Typically sealing indudes a heat seal to insure asepsis.
- a second portal 4 is provided which communicates with a spike 22 coupled via conduit 26 to a separation reagent bag 20 and through conduit 32 to the white cell bag 30 from the second array of bags discussed above.
- the blood bag 10 may also be provided with a third access 6 which may include a sample tube, should it be found desirable to place into storage an exemplar of the cord blood which was originally drawn. Access 6 may also provide alternative connections to bag 10 .
- the admixture with an anticoagulant such as CPD prevents the dotting of the placental blood and readies the blood for admixture with a reagent contained within reagent bag 20 .
- an anticoagulant such as CPD
- the bag is centrifuged at a precise speed and the white-cell-rich supernatant is expressed into the white cell bag 30 .
- the reagent is intended to facilitate the sedimentation of the red blood cells which is greatly accelerated by a very light centrifugation step (50 ⁇ G ⁇ 5 min.).
- the effects of the addition of separation reagent and centrifugation are to produce a supernatant which contains eighty to ninety-five percent (80-95%) of the white blood cells and less than ten percent (10%) of the red blood cells of the originally collected blood. This reduces the presence of red cells (compared to white cells) by approximately ninety percent (90%). In the white cell bag, the red cell to white cell count ratio is now reduced to approximately one hundred (100) to one (1).
- reagents which promote effective separation of the red blood cells from the white blood cells operate on the basis of mechanisms which can be the subject matter of some speculation as to the physical process or model that describes the separation process.
- One vantage point advances the premise that the addition of the reagent raises the dielectric strength of the suspension medium and then, its charge-dissipating capacity, so that the tendency for the red blood cells to remain in uniform suspension is disturbed.
- Another view is that the polymeric molecule of the reagent binds to two or more red blood cells, causing them to aggregate and form characteristic “rouleau” i.e., loose clumps of red blood cells stacked together by the flat aspects of their discoidal surface.
- Reagents which change the charge dissipation characteristic or alter the dielectric strength of the constituent components can be selected from a relatively broad range of suitable substances.
- a six percent (6%) concentration of Heptastarch is presently preferred both due to efficacy, cost, and wide spread utilization in clinical blood processing.
- similar natural polymers such as dextrans, gelatins, modified or unmodified starches or synthetics such as polyethylene glycol or polyvinyl-pirrolydone and many others could conceivably be substituted as conditions warrant.
- a similar effect may also be obtained with substances whose molecules attach with high avidity to two or more red cells such as antibodies and lectins.
- any one of these red cell-cryoprecipitating reagents contained in the reagent bag is dispensed from the reagent bag 20 via outlet 24 through branch passageway 26 and through the outlet spike 22 received by portal 4 or, alternatively, portal 6 , into the blood bag 10 .
- a preferred embodiment provides a reagent bag 20 with a sufficient volume of Hydroxyethyl starch (Heptastarch, Dupont) to provide for the addition of a volume equal to one-fifth (1 ⁇ 5) that of the PB collection into bag 10 .
- one-fifth (1 ⁇ 5) of one hundred (100) milliliters equals twenty (20) milliliters.
- seventy (70) milliliters of white cell enriched supernatant plasma (containing the reagent solution) will be produced which will be expressed into the white cell bag 30 .
- the white cell bag 30 includes an outlet portal 38 that communicates with the plasma bag 40 via a branch conduit 42 having a T-adapter 44 and a constrictor 46 in line.
- the supernatant is expressed from white cell bag 30 via conduit 42 to the plasma bag 40 via its own portal 48 . Once the supernatant has been received into the plasma bag 40 it is sealed off and the plasma bag 40 is disconnected from the white cell bag 30 .
- Cryoprotectant from cryoprotectant bag 50 is next admitted into the white cell bag 30 .
- Cryoprotectant bag 50 includes an outlet 52 , a branch passageway 54 and a constrictor element 56 on the line 54 in fluidic communication with the portal 38 of the white cell bag 30 through T-adapter 44 .
- three point eight (3.8) milliliters of cryoprotectant is admitted into the fifteen (15) milliliters contained within the white cell bag 30 . It is extremely desirable to admit the cryoprotectant into the white cell bag 30 at a relatively slow rate.
- cryoprotectant solution includes Dimethyl Sulfoxide DMSO (an intracellular cryoprotectant) diluted to fifty percent (50%) with dextran an extracellular cryoprotectant.
- constrictor element 56 determines that the intracellular cryoprotectant can only enter white cell bag 30 very slowly. Thus, the intracellular cryoprotectant increases its concentration and permeates the white cell mixture contained within the white cell bag 30 without causing damage to the cells.
- a metering instrumentality 58 may be interposed in the branch 54 instead of the constrictor element 56 (should the constriction not provide a constant flow rate) and in fluid communication with the portal 38 .
- the metering instrumentality 58 can be a pump.
- the cryoprotectant bag and pump arrangement can be replaced with a syringe or other metering apparatus which facilitates the slow addition of cryoprotectant to the white cell bag 30 .
- cryoprotectant The physical analogy for the cryoprotectant is that the DMSO penetrates through the white cell membrane and reduces the capacity of intracellular water as it freezes to crystallize intracellularly and inflict damage to the cell walls. Dextran and other extracellular cryoprotectants such as diverse kinds of soluble starches, proteins and sugars are believed to provide extracellular layers around white cells that insulate the cells from the tendency of the water to form crystals during the freezing process and to develop excessive extracellular hyperosmolarity, both of which might reduce cell wall integrity and cellular viability.
- cryoprotectant By providing the cryoprotectant at a measured rate, over a relatively long period of time, cell viability will have been maximized by providing ample time for the DMSO to diffuse into cells and to reach equilibrium across the cell membrane and for the dextran to be homogeneously diluted in the surrounding plasma.
- three and eight/tenth (3 and 8/10) milliliters of cryoprotectant is added to the fifteen (15) milliliters of white cells in the white cell bag 30 .
- This addition brings the concentration of DMSO to ten percent (10%) in bag 30 .
- White cell bag 30 has another outlet 62 which receives a spike 64 from the stem cell freezing bag 60 in an aseptic manner.
- the white cell bag 30 communicates with stem cell freezing bag 60 via conduit 66 controlled by clamp 67 .
- the cryoprotected white cell mixture is received into the stem cell freezing bag 60 via portal 68 .
- the portal 68 is specially configured to include a stand tube which allows a standing column of stem cell mixture to be retained therewithin for sequestering into a series of compartments 70 , each spaced from the other by heat seals 72 .
- These specimens 70 can be used for pre-infusion confirmation of an optimum HLA match or other tests, once a particular stem cell freezing bag 60 has been chosen as appropriate for the putative recipient.
- the stem cell freezing bag 60 is further characterized by having a plurality of compartments within the main body of the bag 60 , each compartment provided with indicia 75 thereon for identification of the specific unit, establishing a form of chain of custody. More particularly, the stem cell freezing bag 60 includes at least a first major portion 74 and a second minor portion 76 . Typically, the ratio between the major portion 74 and the minor portion 76 is eighty percent (80%) major portion and twenty percent (20%) minor portion. These portions of bag 60 are delimited by heat seal 80 and, after filling, contribute to dividing the stem cell freezing bag into two, intimately attached, but independent white cell containers once heat seals at both locations 82 are executed.
- Each portion is in communication with its own outlet.
- the major portion 74 is in communication with its portal 84 while the minor portion 76 communicates with its own portal 86 .
- the heat seal location may include a line of demarcation 81 defining a scoreline which allows the major portion 74 to be severed, without thawing, from the minor portion 76 .
- the stem cells contained in the minor portion 76 can be allocated for other uses, such as for increasing the numbers of useful cells by culturing the stem and progenitor cells in a propagation medium.
- the stem cells in major portion 74 are left undisturbed for administration as transplants.
- the freezer bag 60 and stand tube/portal 68 have negligible thickness. The purpose of this particular geometry is to assure that the white cells in compartments 76 , 74 and 70 all maintain a uniform and narrow thickness so that subsequent freezing regimens achieve near identical controlled rate freezing conditions.
- the freezing bag 60 approximately nineteen (19) milliliters of therapeutic product are contained within the freezing bag 60 .
- the stem cell freezing bag 60 is gradually frozen to an extremely low temperature such as in liquid nitrogen for permanent storage. This preserves the stem cells in a state such that, upon thawing, they are recovered in quantity and exhibit a high degree of cell viability.
- the stem cells are first thawed to a temperature where the stem cells and constituent components change phase back from a solid to a liquid.
- the stem cells are washed to remove the cryoprotectant which was added prior to freezing.
- the wash is intended to remove the DMSO by using an isotonic fluid, preferably a colloid.
- an isotonic fluid preferably a colloid.
- a mixture having five percent (5%) albumin and ten percent (10%) dextran in a saline solution is used to dilute the DMSO in the extracellular environment and secondarily reduce its concentration inside the white blood cells.
- the mixture is centrifuged at four hundred (400) gs for ten (10) minutes with the supernatant expressed therefrom.
- the enriched white cells were present in volume at approximately fifteen (15) milliliters prior to the addition of three point eight (3.8) milliliters of cryoprotectant.
- the stem cell freezing bag When placed in the stem cell freezing bag, about four (4) milliliters were placed in the secondary compartment 76 and fifteen (15) milliliters were retained in the primary container 74 .
- somewhat less than the four (4) milliliters are allocated as is just described because the stem cell samples contained within compartments 70 may contain collectively up to one (1) milliliter.
- the thawed white blood and stem cell suspension prior to washing contained ten (10%) cryoprotectant by volume.
- the sedimented stem cells (typically in a volume less than three (3) milliliters) are diluted once again to a volume adequate for administration to the recipient, fifteen (15) milliliters or more.
- This second dilution reduces the concentration of DMSO to below one percent (1%). Therefore, the quantity of DMSO retained is in the order to one-tenth ( 1/10) gram. This is very much less, compared with the prior art which typically may have involved two hundred (200) milliliters of ten percent (10%) DMSO i.e. twenty (20) grams of this compound.
- the therapeutic dose described in the disclosed invention hereinabove has a special efficacy because the processing described hereinabove has removed from the whole blood, the bulk of the red cells, plasma, cryoprotectant, free hemoglobin, etc. which heretofore have exhibited adverse consequences on the recipient and has restored the osmolarity of the stem and progenitor cells to the normal range of three hundred (300) milliosmols from the over one thousand (1000) milliosmols of ten percent (10%) DMSO solution.
- the stem cells that are stored in freezing bags must be kept at extremely low temperatures such as those achievable using liquid nitrogen.
- the problems that would have existed before in the provision of storage space for units with ten fold larger volumes of cryopreserved placental blood (whole) will have been solved by the smaller storage requirement of separated white blood cells associated with the instant invention.
- the therapeutic dose involves a relatively low level of DMSO in the finished product that is to be administered.
- a second attribute involves the fact that a ten (10) fold lower concentration of red blood cells are contained in a unit without significant loss of stem and progenitor cells.
- the lower red blood cell numbers reduce the presence of hemoglobin in the thawed specimen and decrease the problems associated with red blood cell incompatibilities.
- the viability of the white cells contained in the dose after thawing is typically three (3) to four (4) fold higher than in the prior art, particularly after administration and dilution in the recipient's own plasma.
- thawed white cells are diluted in twenty (20) milliliters of plasma prior to counting for viability.
- unwashed white cell viability was typically of the order of twenty percent (20%).
- the mononuclear cells are much greater than twenty percent (20%), typically greater than ninety percent (90%) viable.
- stem and progenitor cells are cultured in vitro from such white cell concentrates after thawing as described, the number of viable cells estimated by the number of colonies formed is also greater than ninety percent (90%) of the original numbers.
Abstract
A therapeutic product formed from a high concentration of white blood cells having a high degree of cell viability. The white blood cells are sequestered from their normal population presence in whole blood by placing the blood into a container and preventing coagulation of the blood, separating the blood into two components, one of which is extremely rich in white blood cells through the use of a reagent and centrifugation, sequestering the white cell concentration, and freezing the white cells.
Description
- The following invention is directed generally to the therapeutic utilization of white blood cells, a technique for sequestering the white blood cells by causing them to coalesce in a population density greater than they normally occur in nature, and a method for causing an enriched concentration in conjunction with an array of bags oriented in a set that facilitates both the concentration process and a method for preserving the white blood cells.
- It is now recognized that placenta/umbilical cord blood (PB) contains large numbers of hematopoietic stem and progenitor cells that endow PB with extraordinary therapeutic capabilities in the reconstitution of bone marrow damaged as a result of inherited diseases, accidents or medical procedures. As in the case of ordinary collection of bone marrow for transplantation, PB contains immune cells potentially capable of mounting specific responses against the recipients of such transplants, but in contrast to adult immunological cells, those in PB display a lower, perhaps much lower tendency to produce damaging immune responses against the recipient. The clinical syndrome produced by the immuno responses of the graft against the recipient's cells and tissues is designated “Graft versus Host Disease” (GVHD). In the typical clinical situation, the recipient's own immune response against the graft is abrogated by drugs and irradiation treatments designed to reduce or eliminate the immunological and other hematopoietic cells and thus avoid the host versus graft immune reaction that would cause rejection of the graft. It has been proven that the principal targets of these Graft versus Host and Host versus Graft immune reactions are antigens encoded by the genes of the HLA (Human Leukocyte Antigen) system and that successful outcomes of bone marrow transplants are dependent on the sharing of HLA antigens by donor and recipient. Sibling donors who have inherited the same paternal and maternal HLA genes present in the recipient are HLA-identical and thus, optimal from this viewpoint. Patients lacking such HLA-identical sibling donors must receive transplants from more distant relatives or from unrelated donors. Because the HLA system includes several discrete genes each of which displays an extremely large number of antigenically different variants in the population, such distant relative-donor or unrelated-donor transplants must be expected to contain a variable number of HLA incompatibilities unless they are selected from among potential donors by identifying the specific variants present in each and choosing donors whose HLA antigens match those of the recipient. To perform this selection with significant probability of success, it is necessary to have access to large panels of potential donors whose HLA antigens are known. In the case of unrelated donor PB, this requires establishing a bank of frozen HLA-typed units collected from random placentas. Heretofore, the most widely accepted method for freezing PB consisted of adding to the whole PB unit an equal volume of a cryopreservative solution, with the double disadvantage that the volume of each cryopreserved unit becomes very large and that a relatively large amount of possibly deleterious cryopreservative is eventually administered to the recipients of such PB units. Administration of crybprotectant and hemoglobin from erythrocytes destroyed by using a freezing and thawing method designed to protect the stem and progenitor cells but not the erythrocytes may have toxic effects generally and especially on specific organs such as the kidney of the recipient. In addition, there is the logistical consequence that a large number of freezers would be needed to contain useful numbers of the large volume frozen units in reserve, with the attending increase in up-front and running costs. The applicants have developed a practical method that allows a substantial reduction of the volume of PB Units by eliminating the unneeded mature red blood cells and an equivalent volume of plasma. This submission describes this method and a specially designed set of plastic bags and connecting tubes intended to facilitate the accomplishment of the desired concentration of the needed stem cells and progenitor cells with minimal manipulation and risk of contamination. Essentially, this method will allow an experimental, time consuming laboratory process to become a routine procedure in blood banks.
- The following submission reflects the state of the art of which applicant is aware insofar as these documents appear germane to the patent process. However, it is respectfully stipulated that none of these patents teach singly nor render obvious when considered in any conceivable combination the nexus of the instant invention as set forth hereinafter.
INVENTOR PATENT NO. ISSUE DATE Tenczar, Jr. 3,187,750 June 1965 Williams 4,332,122 June 1982 Pattillo, et al. 4,937,194 June 1990 Boyse, et al. 5,004,681 April 1991 Carmen, et al. 5,104,788 April 1992 Bauman, et al. 5,154,716 October 1992 Boyse, et al. 5,192,553 March 1993 - (Including Author, Title, Date, Pertinent Pages, Etc.)
- Pablo Rubinstein, Richard E. Rosenfield, Jonh W. Adamson and Cladd E. Stevens (The Lindsley F. Kimball Resaerch INstitue of The New York Blood Ceneter); Stored Placental Blood for Unrelated Bone Marrow Reconstruction; May, 1993; entire paper.
- The therapeutic product of the present invention is advantageous, first, because it recovers all or almost all of the stem and progenitor cells of the original collection of PB in a small and uniform volume that requires minimal and predictable storage space, second, because it permits a consistent methodology for processing PB units which results in a routinely dependable product with less dependence on operator skill and third, because the potentially deleterious effects of the cryoprotectant and of the free hemoglobin are minimized.
- One first aspect to the nature of the product improved according to the present invention involves the methodology by which the white blood cells (which include the hematopoietic stem and progenitor cells) are separated from the bulk of other components in the whole PB and the manner in which the viability of such white cells is preserved by avoiding exposure to bacterial and fungal contamination, potentially damaging chemical agents, excessive centrifugal forces and osmotic imbalances. Typically, bacterial and/or fungal contamination occurs when PB or white blood cell suspensions derived from PB are exposed to ambient air in the course of preparatory manipulations; chemical damage is possible when certain chemicals are used to lyse the accompanying red blood cells or to aggregate white cells; and physical damage follows the use of excessive centrifugal speed in separation of the cellular components of the blood according to their density, by centrifugal stratification. In addition, the method according to the present invention provides for avoidance of prolonged exposure of the separated white blood cells to cryopreservation solutions at room temperature, an exposure that results in decreased viability of the white blood cells and of the stem and progenitor cells contained therein because of osmotic imbalances and, possibly, other toxic effects of the intracellular cryoprotectants themselves.
- Another aspect of the present invention involves the set of interconnected plastic containers (designated as bags). The set under the present invention permits a selective concentration of the white blood cells and of the stem and progenitor cells contained therein without reducing their normally high viability and freedom from contamination by infectious organisms from the environment. Whole PB is collected into a mother bag and is subsequently processed through a series of bags of appropriate chemical structure and physical shape and capacity culminating in storage of a separated fraction containing most of the white blood cells of the collected PB in liquid nitrogen at −196 C inside a specially constructed freezer bag. Intervening steps include the addition of substances that enhance the aggregability of red blood cells and the separation of components by transferring supernatants into connected satellite bags. A special bag and its connecting assembly permits the addition of measured amounts of cryoprotectant to the separated white blood cell concentrate. This connecting assembly allows the cryoprotectant to be added to the white cells at a precise, slow speed required to maintain optimal cell viability.
- The bag which is to be used for freezing and storage includes a plurality of connected, but detachable compartments for sequestration of the white blood cells into different discrete chambers. One chamber, the main compartment, is intended to keep the bulk of the white blood cells. A smaller compartment lends itself to the storage of a smaller fraction of the bag contents which may be separated from the main compartment without thawing, and extemporaneously detached from it for separate thawing and subsequent in vitro expansion of the hematopoietic stem and progenitor cell populations contained in the corresponding fraction of the white blood cells. A third and subsequent chamber contains very small aliquots of the white blood cell suspension and are intended to serve as detachable samples for testing the aptness of the unit to be transplanted or assessing its suitability as donor tissue for a specific recipient. The freezing bag also indudes indicia on the outer surface of each of its detachable areas for identification of the specific unit that will be stored in it, to facilitate storage and retrieval from designated sectors of cryogenic storage depots. Means are also provided in an exterior surface of the freezer bag to facilitate the placing and removing of the freezer bag into and from, respectively, its assigned storage location by automated instrumentation.
- Accordingly, it is a primary object of the present invention to provide the means for preparing PB derived hematopoietic stem and progenitor cells in a novel and therapeutically more useful form. The product becomes a bag containing a high concentration of white blood cells having a high degree of cell viability.
- A further object of the present invention is to provide a novel and useful method for generating the therapeutic product according to the previous object.
- A further object of the present invention is to provide an aseptic and interconnected bag set for use in conjunction with the method of developing the therapeutic product hereinabove.
- A further object of the present invention is to provide a freezer storage bag configured to contain the therapeutic dose in a cryoprotected environment for protracted periods of time until needed for dosage.
- A further object of the present invention is to provide a freezer bag as noted above provided with a plurality of compartments in which the therapeutic dose has been sequestered so that various aliquots can be strategically excised from the freezer bag for several purposes.
- Viewed from a first vantage point, it is an object of the present invention to provide a system for developing placental stem cells, comprising in combination: a first blood bag adapted to receive blood from a placenta therewithin, means within the blood bag to prevent coagulation, reagent means removably coupled to the blood bag, means for separating supernatant from the first blood bag and into a white cell bag, means for separating white cells from plasma in the white cell bag, a plasma bag removably coupled to the white cell bag for receiving the expressed plasma from the white cell bag, cryoprotectant means operatively coupled to the white cell bag, and a stem cell freezing bag operatively coupled to the white cell bag for transferring contents from the white cell bag to the stem cell freezing bag.
- Viewed from a second vantage point, it is an object of the present invention to provide a method for preparing concentrated and partially purified white blood cell suspensions containing placental stem cells, comprising the steps of: placing blood from a placenta into a first blood bag, preventing coagulation within the blood bag, coupling reagent means into the blood bag, centrifuging and separating white blood cell rich supernatant from the first blood bag and placing the supernatant into a white cell bag, separating white cells from plasma in the white cell bag, removably coupling a plasma bag to the white cell bag and expressing the plasma from the white cell bag into the plasma bag. Coupling cryoprotectant means to the white cell bag, transferring contents from the white cell bag to a stem cell freezing bag, and freezing the stem cell freezing bag with its contents follows.
- Viewed from a third vantage point, it is an object of the present invention to provide a therapeutic product comprising at least 80% of the white blood cells (including stem and progenitor cells) with viability greater than 90% and fewer than 10% of the red blood cells in the original PB collection.
- These and other objects will be made manifest when considering the following detailed specification when taken in conjunction with the appended drawing figures.
-
FIG. 1 is a schematic view of the stem cell processing bag set according to the present invention. -
FIG. 2 is a detailed view of the freezing bag shown inFIG. 1 . -
FIG. 3 is a view similar toFIG. 2 showing the interior of the freezing bag. -
FIG. 4 is a flow chart the method according to the present invention. - Referring to the drawings now, wherein like reference numerals refer to like parts throughout various figures,
reference numeral 100 is directed to an apparatus according to the present invention. - In essence, the
apparatus 100 may be viewed as three arrays of bags collectively defining a bag set. Individual bags are provided with removable connection means to assure selected admission into the several bags only under aseptic conditions. In a preferred form of the invention, the array ofbags 100 includes six bags: ablood bag 10 defining a first array; areagent bag 20, awhite cell bag 30, aplasma bag 40 and acryoprotectant bag 50 defining a second array; and a stemcell freezing bag 60 defining a third array. Cord blood (i.e. blood from the placenta and umbilical cord) is admitted to theblood bag 10 which had previously been dosed with an anticoagulant. Next, the second array is connected to theblood bag 10. A separation reagent is admitted to the blood bag viaconduit 26 fromreagent bag 20. Centrifugingblood bag 10 follows. Supernatant containing the white blood cells is expressed off into thewhite cell bag 30, whereupon further centrifugation takes place. Next, supernatant plasma is expressed off into theplasma bag 40 leaving sedimented white blood cells inwhite cell bag 30. Cryoprotectant from thecryoprotectant bag 50 is transferred viaconduit 59 to thewhite cell bag 30 slowly. Subsequently, the contents of thewhite cell bag 30 are transferred to the stemcell freezing bag 60 which is thereafter frozen and stored in liquid nitrogen for subsequent use. - More specifically, and with reference to
FIG. 1 , whole, placental, and umbilical cord blood is collected into ablood bag 10 provided with an anticoagulant such as Citrate, Phosphate and Dextrose (CPD). Assume, for the sake of explanation, that one hundred (100) milliliters of blood are placed within the blood bag. Typically, cord blood will exhibit a ratio of one thousand (1,000) red cells to each “non-red” cell (for simplicity, assume the non-red blood cell can be labeled white blood cells). Naturally, the main recognizable and functionally capable cells circulating in blood include erythrocytes, neutrophilic, eosinophilic, and basophilic granulocytes; B- T- and non B- non T-lymphocytes; monocytes and platelets. These mature cells derive from and are replaced, on demand, by morphologically recognizable dividing precursor cells for the respective lineages such as erythroblasts for the erythrocyte series, myeloblasts, promyelocytes and myelocytes for the granulocyte series, and megakaryocytes for the platelets. The precursor cells derive from more primitive cells that can simplistically be divided into two major subgroups: stem cells and progenitor cells. Of course, neonatal blood has other cellular constituents which will not be discussed here so as not to obscure the essence of the invention. Theblood bag 10 includes at least two access portals. A first portal 2 receives the cord blood whereupon the access portal 2 is sealed. Typically sealing indudes a heat seal to insure asepsis. Asecond portal 4 is provided which communicates with aspike 22 coupled viaconduit 26 to aseparation reagent bag 20 and throughconduit 32 to thewhite cell bag 30 from the second array of bags discussed above. In addition, theblood bag 10 may also be provided with athird access 6 which may include a sample tube, should it be found desirable to place into storage an exemplar of the cord blood which was originally drawn.Access 6 may also provide alternative connections tobag 10. - Once the cord blood has been admitted into the
blood bag 10, the admixture with an anticoagulant such as CPD prevents the dotting of the placental blood and readies the blood for admixture with a reagent contained withinreagent bag 20. After the admission of the reagent to the blood bag and thorough mixing, the bag is centrifuged at a precise speed and the white-cell-rich supernatant is expressed into thewhite cell bag 30. The reagent is intended to facilitate the sedimentation of the red blood cells which is greatly accelerated by a very light centrifugation step (50×G×5 min.). The effects of the addition of separation reagent and centrifugation are to produce a supernatant which contains eighty to ninety-five percent (80-95%) of the white blood cells and less than ten percent (10%) of the red blood cells of the originally collected blood. This reduces the presence of red cells (compared to white cells) by approximately ninety percent (90%). In the white cell bag, the red cell to white cell count ratio is now reduced to approximately one hundred (100) to one (1). - Typically, reagents which promote effective separation of the red blood cells from the white blood cells operate on the basis of mechanisms which can be the subject matter of some speculation as to the physical process or model that describes the separation process. One vantage point advances the premise that the addition of the reagent raises the dielectric strength of the suspension medium and then, its charge-dissipating capacity, so that the tendency for the red blood cells to remain in uniform suspension is disturbed. Another view is that the polymeric molecule of the reagent binds to two or more red blood cells, causing them to aggregate and form characteristic “rouleau” i.e., loose clumps of red blood cells stacked together by the flat aspects of their discoidal surface. The effect, however, irrespective of the physical model that one envisions, is that separation between the red and white cells is possible with relatively minor, gentle and brief centrifugation. This accelerates the settling of the red cells and preserves the white cells in the suspended, unmodified state. In a preferred embodiment, once the reagent from
bag 20 has been placed within theblood bag 10, centrifugation at fifty (50) gs for approximately five (5) minutes provides effective separation. - Reagents which change the charge dissipation characteristic or alter the dielectric strength of the constituent components can be selected from a relatively broad range of suitable substances. A six percent (6%) concentration of Heptastarch is presently preferred both due to efficacy, cost, and wide spread utilization in clinical blood processing. However, similar natural polymers such as dextrans, gelatins, modified or unmodified starches or synthetics such as polyethylene glycol or polyvinyl-pirrolydone and many others could conceivably be substituted as conditions warrant. A similar effect may also be obtained with substances whose molecules attach with high avidity to two or more red cells such as antibodies and lectins. In any event, any one of these red cell-cryoprecipitating reagents contained in the reagent bag is dispensed from the
reagent bag 20 viaoutlet 24 throughbranch passageway 26 and through theoutlet spike 22 received byportal 4 or, alternatively,portal 6, into theblood bag 10. - Mixing of the reagent with the blood in the
bag 10 followed by gentle centrifugation results in a separation in which the supernatant composed of plasma, most of the white blood cells and a small fraction of the red blood cells, is expressed off into thewhite cell bag 30 via abranch passageway 32 communicating between thespike 22 and thebag 30 with a T-adapter 34 which allows a bifurcation between thebranch 26 and thebranch 32. The bulk of the red blood cells remain inbag 10. The enriched white cell mixture is prevented from entering the reagent bag by means of aclamp 28 operatively engaged on thebranch passage 26. The enriched white cell mixture in thewhite cell bag 30 atinlet 36 is now ready for further processing. - As an example, assume one hundred (100) milliliters of PB had been originally collected into
blood bag 10. A preferred embodiment provides areagent bag 20 with a sufficient volume of Hydroxyethyl starch (Heptastarch, Dupont) to provide for the addition of a volume equal to one-fifth (⅕) that of the PB collection intobag 10. In this example, one-fifth (⅕) of one hundred (100) milliliters equals twenty (20) milliliters. Typically, seventy (70) milliliters of white cell enriched supernatant plasma (containing the reagent solution) will be produced which will be expressed into thewhite cell bag 30. Once there, the contents are subjected to further centrifugation at four hundred (400)×G×ten (10) minutes. Typically, of the seventy (70) milliliters that had been admitted into thewhite cell bag 30, fifty-five (55) milliliters will be expressed off thereafter into aplasma bag 40, leaving approximately fifteen (15) milliliters of highly-enriched white cell product inbag 30. The supernatant transferred tobag 40 contains the bulk of the plasma, anticoagulant and reagent and essentially no cells. - The
white cell bag 30 includes anoutlet portal 38 that communicates with theplasma bag 40 via abranch conduit 42 having a T-adapter 44 and aconstrictor 46 in line. The supernatant is expressed fromwhite cell bag 30 viaconduit 42 to theplasma bag 40 via itsown portal 48. Once the supernatant has been received into theplasma bag 40 it is sealed off and theplasma bag 40 is disconnected from thewhite cell bag 30. - Cryoprotectant from
cryoprotectant bag 50 is next admitted into thewhite cell bag 30.Cryoprotectant bag 50 includes anoutlet 52, a branch passageway 54 and aconstrictor element 56 on the line 54 in fluidic communication with the portal 38 of thewhite cell bag 30 through T-adapter 44. Typically, three point eight (3.8) milliliters of cryoprotectant is admitted into the fifteen (15) milliliters contained within thewhite cell bag 30. It is extremely desirable to admit the cryoprotectant into thewhite cell bag 30 at a relatively slow rate. Typically, the three point eight (3.8) milliliters of cryoprotectant is admitted into the bag over a twenty (20) minute interval, while continuously mixing the cryoprotectant with the contents of the white cell bag by hand or with an orbital shaker. A preferred cryoprotectant solution includes Dimethyl Sulfoxide DMSO (an intracellular cryoprotectant) diluted to fifty percent (50%) with dextran an extracellular cryoprotectant. One feature of the instant invention is that theconstrictor element 56 determines that the intracellular cryoprotectant can only enterwhite cell bag 30 very slowly. Thus, the intracellular cryoprotectant increases its concentration and permeates the white cell mixture contained within thewhite cell bag 30 without causing damage to the cells. In order to effect same, ametering instrumentality 58 may be interposed in the branch 54 instead of the constrictor element 56 (should the constriction not provide a constant flow rate) and in fluid communication with the portal 38. Themetering instrumentality 58 can be a pump. Alternatively the cryoprotectant bag and pump arrangement can be replaced with a syringe or other metering apparatus which facilitates the slow addition of cryoprotectant to thewhite cell bag 30. - The physical analogy for the cryoprotectant is that the DMSO penetrates through the white cell membrane and reduces the capacity of intracellular water as it freezes to crystallize intracellularly and inflict damage to the cell walls. Dextran and other extracellular cryoprotectants such as diverse kinds of soluble starches, proteins and sugars are believed to provide extracellular layers around white cells that insulate the cells from the tendency of the water to form crystals during the freezing process and to develop excessive extracellular hyperosmolarity, both of which might reduce cell wall integrity and cellular viability. By providing the cryoprotectant at a measured rate, over a relatively long period of time, cell viability will have been maximized by providing ample time for the DMSO to diffuse into cells and to reach equilibrium across the cell membrane and for the dextran to be homogeneously diluted in the surrounding plasma.
- As an example of the preferred embodiment, three and eight/tenth (3 and 8/10) milliliters of cryoprotectant is added to the fifteen (15) milliliters of white cells in the
white cell bag 30. This addition brings the concentration of DMSO to ten percent (10%) inbag 30.White cell bag 30 has anotheroutlet 62 which receives aspike 64 from the stemcell freezing bag 60 in an aseptic manner. Thewhite cell bag 30 communicates with stemcell freezing bag 60 viaconduit 66 controlled byclamp 67. The cryoprotected white cell mixture is received into the stemcell freezing bag 60 viaportal 68. The portal 68 is specially configured to include a stand tube which allows a standing column of stem cell mixture to be retained therewithin for sequestering into a series ofcompartments 70, each spaced from the other by heat seals 72. Thesespecimens 70 can be used for pre-infusion confirmation of an optimum HLA match or other tests, once a particular stemcell freezing bag 60 has been chosen as appropriate for the putative recipient. - The stem
cell freezing bag 60 is further characterized by having a plurality of compartments within the main body of thebag 60, each compartment provided withindicia 75 thereon for identification of the specific unit, establishing a form of chain of custody. More particularly, the stemcell freezing bag 60 includes at least a firstmajor portion 74 and a secondminor portion 76. Typically, the ratio between themajor portion 74 and theminor portion 76 is eighty percent (80%) major portion and twenty percent (20%) minor portion. These portions ofbag 60 are delimited byheat seal 80 and, after filling, contribute to dividing the stem cell freezing bag into two, intimately attached, but independent white cell containers once heat seals at bothlocations 82 are executed. - Each portion is in communication with its own outlet. The
major portion 74 is in communication with its portal 84 while theminor portion 76 communicates with itsown portal 86. In addition, the heat seal location may include a line ofdemarcation 81 defining a scoreline which allows themajor portion 74 to be severed, without thawing, from theminor portion 76. It is contemplated that the stem cells contained in theminor portion 76 can be allocated for other uses, such as for increasing the numbers of useful cells by culturing the stem and progenitor cells in a propagation medium. The stem cells inmajor portion 74 are left undisturbed for administration as transplants. Thefreezer bag 60 and stand tube/portal 68 have negligible thickness. The purpose of this particular geometry is to assure that the white cells incompartments - In a preferred embodiment, approximately nineteen (19) milliliters of therapeutic product are contained within the freezing
bag 60. The stemcell freezing bag 60 is gradually frozen to an extremely low temperature such as in liquid nitrogen for permanent storage. This preserves the stem cells in a state such that, upon thawing, they are recovered in quantity and exhibit a high degree of cell viability. - Once it has been determined that the given stem cells within a freezing
bag 60 are to be used in a transplant procedure, the stem cells are first thawed to a temperature where the stem cells and constituent components change phase back from a solid to a liquid. Next, the stem cells are washed to remove the cryoprotectant which was added prior to freezing. Preferably, the wash is intended to remove the DMSO by using an isotonic fluid, preferably a colloid. For example, a mixture having five percent (5%) albumin and ten percent (10%) dextran in a saline solution is used to dilute the DMSO in the extracellular environment and secondarily reduce its concentration inside the white blood cells. Subsequently, the mixture is centrifuged at four hundred (400) gs for ten (10) minutes with the supernatant expressed therefrom. - As mentioned supra, the enriched white cells were present in volume at approximately fifteen (15) milliliters prior to the addition of three point eight (3.8) milliliters of cryoprotectant. When placed in the stem cell freezing bag, about four (4) milliliters were placed in the
secondary compartment 76 and fifteen (15) milliliters were retained in theprimary container 74. In actuality, somewhat less than the four (4) milliliters are allocated as is just described because the stem cell samples contained withincompartments 70 may contain collectively up to one (1) milliliter. In any event, the thawed white blood and stem cell suspension prior to washing contained ten (10%) cryoprotectant by volume. After the dilution, spinning and expressing off the supernatant the sedimented stem cells (typically in a volume less than three (3) milliliters) are diluted once again to a volume adequate for administration to the recipient, fifteen (15) milliliters or more. This second dilution reduces the concentration of DMSO to below one percent (1%). Therefore, the quantity of DMSO retained is in the order to one-tenth ( 1/10) gram. This is very much less, compared with the prior art which typically may have involved two hundred (200) milliliters of ten percent (10%) DMSO i.e. twenty (20) grams of this compound. - In addition, the therapeutic dose described in the disclosed invention hereinabove has a special efficacy because the processing described hereinabove has removed from the whole blood, the bulk of the red cells, plasma, cryoprotectant, free hemoglobin, etc. which heretofore have exhibited adverse consequences on the recipient and has restored the osmolarity of the stem and progenitor cells to the normal range of three hundred (300) milliosmols from the over one thousand (1000) milliosmols of ten percent (10%) DMSO solution.
- It is to be noted that the stem cells that are stored in freezing bags must be kept at extremely low temperatures such as those achievable using liquid nitrogen. By providing white stem cells in twenty (20) milliliter quantities, the problems that would have existed before in the provision of storage space for units with ten fold larger volumes of cryopreserved placental blood (whole) will have been solved by the smaller storage requirement of separated white blood cells associated with the instant invention.
- One attribute of the instant invention is that the therapeutic dose involves a relatively low level of DMSO in the finished product that is to be administered. A second attribute involves the fact that a ten (10) fold lower concentration of red blood cells are contained in a unit without significant loss of stem and progenitor cells. The lower red blood cell numbers reduce the presence of hemoglobin in the thawed specimen and decrease the problems associated with red blood cell incompatibilities. Further, the viability of the white cells contained in the dose after thawing is typically three (3) to four (4) fold higher than in the prior art, particularly after administration and dilution in the recipient's own plasma. Experimentally, thawed white cells are diluted in twenty (20) milliliters of plasma prior to counting for viability. In prior art, unwashed white cell viability was typically of the order of twenty percent (20%). According to the present invention, using the DNA fluorescence stain or other viability tests, the mononuclear cells are much greater than twenty percent (20%), typically greater than ninety percent (90%) viable. When stem and progenitor cells are cultured in vitro from such white cell concentrates after thawing as described, the number of viable cells estimated by the number of colonies formed is also greater than ninety percent (90%) of the original numbers.
- While the previous discussion has focused on the desirability of using cord blood from placental stem cells, other peripheral stem cells can also be processed in a similar manner to provide benefits. Further, having thus described the invention it should be apparent that numerous structural modification and adaptations of the bag set, the chemical nature of the reagents and cryoprotectants and the details of the processing steps, may be resorted to without departing from the scope and fair meaning of the instant invention as set forth hereinabove and as described hereinbelow by the claims.
Claims (21)
1-24. (canceled)
25. A therapeutic product produced by a process comprising performing the following sequential steps in a series of removably coupled, interconnected bags under aseptic conditions:
(a) centrifuging a sample of placental, umbilical cord and/or peripheral donor blood, which has been contacted with an anticoagulant to prevent coagulation of the donor blood, in a blood bag in the presence of a red blood cell sedimentation reagent at a speed sufficient to obtain a first sediment and a first supernatant, wherein the first sediment comprises at least 90% of red blood cells contained in the blood sample and the first supernatant comprises at least 80% of white blood cells contained in the blood sample;
(b) introducing the first supernatant into a white cell bag;
(c) centrifuging the white cell bag to obtain a second sediment and a second supernatant; and
(d) removing all or a portion of the second supernatant so as to retain in the white cell bag a composition comprising at least 80% of white blood cells contained in the blood sample, less than 10% of red blood cells contained in the blood sample, and less than all of plasma contained in the blood sample.
26. The therapeutic product of claim 25 , wherein the sedimentation reagent comprises hydroxyethyl starch.
27. The therapeutic product of claim 25 , wherein the process further comprises contacting the composition with a cryoprotectant at a rate and an amount sufficient to obtain a cryoprotected composition without damaging cells contained in the composition; and freezing the cryoprotected composition.
28. The therapeutic product of claim 27 , wherein the cryoprotectant comprises dimethylsulfoxide.
29. The therapeutic product of claim 28 , wherein the cryoprotectant further comprises dextran.
30. The therapeutic product of claim 28 , wherein the final concentration of dimethylsulfoxide in the cryoprotected composition is 10%.
31. The therapeutic product of claim 25 , wherein the donor blood is placental blood.
32. The therapeutic product of claim 25 , wherein the donor blood is umbilical cord blood.
33. The therapeutic product of claim 25 , wherein the donor blood is peripheral blood.
34. The therapeutic product of claim 25 , which comprises at least 80% of white blood cells contained in the blood sample, less than 10% of red blood cells contained in the blood sample, and less than all of plasma contained in the blood sample.
35. The therapeutic product of claim 25 , which comprises a red blood cell sedimentation reagent.
36. The therapeutic product of claim 25 , which has a volume of 10 milliliters to 20 milliliters.
37. The therapeutic product of claim 25 , which has an osmolarity of not more than 300 milliosmols.
38. The therapeutic product of claim 25 , wherein the red cell to white cell count is approximately one hundred (100) to one (1).
39. The therapeutic product of claim 25 , which comprises an anticoagulant.
40. The therapeutic product of claim 39 , wherein the anticoagulant comprises Citrate, Phosphate, and Dextrose (CPD).
41. The therapeutic product of claim 27 , wherein the therapeutic product comprises a cryoprotectant.
42. The therapeutic product of claim 28 , wherein the therapeutic product comprises dimethylsulfoxide.
43. The therapeutic product of claim 29 , wherein the therapeutic product comprises dextran.
44. The therapeutic product of claim 29 , wherein the therapeutic product comprises dimethylsulfoxide diluted to 50% with dextran.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/640,138 US20070179424A1 (en) | 1994-12-05 | 2006-12-15 | High concentration white cells, a method for agglomeration of the high concentration and a bag set for use in conjunction therewith |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/349,747 US5789147A (en) | 1994-12-05 | 1994-12-05 | Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood |
US09/128,208 US5928214A (en) | 1994-12-05 | 1998-08-03 | High concentration white cells, a method for agglomeration of the high concentration and a bag set for use in conjunction therewith |
US09/313,816 US6491678B1 (en) | 1994-12-05 | 1999-05-18 | Freezer bag |
US09/855,789 US7169547B2 (en) | 1994-12-05 | 2001-05-15 | High concentration white blood cells as a therapeutic product |
US11/640,138 US20070179424A1 (en) | 1994-12-05 | 2006-12-15 | High concentration white cells, a method for agglomeration of the high concentration and a bag set for use in conjunction therewith |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/855,789 Continuation US7169547B2 (en) | 1994-12-05 | 2001-05-15 | High concentration white blood cells as a therapeutic product |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070179424A1 true US20070179424A1 (en) | 2007-08-02 |
Family
ID=26826390
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/855,789 Expired - Lifetime US7169547B2 (en) | 1994-12-05 | 2001-05-15 | High concentration white blood cells as a therapeutic product |
US11/640,138 Abandoned US20070179424A1 (en) | 1994-12-05 | 2006-12-15 | High concentration white cells, a method for agglomeration of the high concentration and a bag set for use in conjunction therewith |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/855,789 Expired - Lifetime US7169547B2 (en) | 1994-12-05 | 2001-05-15 | High concentration white blood cells as a therapeutic product |
Country Status (1)
Country | Link |
---|---|
US (2) | US7169547B2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080248081A1 (en) * | 2002-04-13 | 2008-10-09 | Bioparadox, Llc | Method of treating chronic dysfunction of cardiac muscle |
US20080248085A1 (en) * | 2002-04-13 | 2008-10-09 | Bioparadox, Llc | Method of tissue vascularization |
US20090092679A1 (en) * | 2004-08-20 | 2009-04-09 | Allan Mishra | Particle/cell separation device and compositions |
US20100092444A1 (en) * | 2008-10-09 | 2010-04-15 | Bioparadox, Llc | Platelet rich plasma formulations for cardiac treatments |
US20100112081A1 (en) * | 2008-10-07 | 2010-05-06 | Bioparadox, Llc | Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities |
US20100233282A1 (en) * | 2009-03-13 | 2010-09-16 | Allan Mishra | Device and methods for delivery of bioactive materials to the right side of the heart |
US20140221958A1 (en) * | 2013-01-31 | 2014-08-07 | Biomet Biologics, Llc | Functionally-closed, sterile blood processing solution system and method |
US9808487B2 (en) | 2013-01-31 | 2017-11-07 | Biomet Biologics, Llc | Methods for rejuvenating red blood cells |
US9950012B2 (en) | 2013-01-31 | 2018-04-24 | Biomet Biologics, Llc | Methods for rejuvenating red blood cells |
US10214727B2 (en) | 2013-06-04 | 2019-02-26 | Allan Mishra | Platelet-rich plasma compositions and methods of preparation |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7169547B2 (en) * | 1994-12-05 | 2007-01-30 | New York Blood Center, Inc. | High concentration white blood cells as a therapeutic product |
JP2004529076A (en) * | 2000-12-05 | 2004-09-24 | ハーベスト・テクノロジーズ・コーポレイション | Erythrocyte sedimentation method |
US20040254560A1 (en) * | 2003-06-11 | 2004-12-16 | Coelho Philip H. | Rupture resistant blow molded freezer bag for containing blood products |
US7442178B2 (en) * | 2005-03-09 | 2008-10-28 | Jacques Chammas | Automated system and method for blood components separation and processing |
DE102008004977A1 (en) * | 2008-01-17 | 2009-07-23 | Miltenyi Biotec Gmbh | Device for the removal of biological material |
US20100210989A1 (en) * | 2008-12-23 | 2010-08-19 | Janet Lesley Macpherson | Processing blood |
WO2011095964A1 (en) * | 2010-02-03 | 2011-08-11 | Fuil Technologies Limited | A method and apparatus for separating a liquid component from a liquid medium |
US9164079B2 (en) * | 2011-03-17 | 2015-10-20 | Greyledge Technologies Llc | Systems for autologous biological therapeutics |
DE102011105311A1 (en) * | 2011-06-19 | 2012-12-20 | Walter Pobitschka | Separation procedure for blood, separation vessel for a blood centrifuge, system for filling a freezing container |
EP2889024B1 (en) * | 2012-08-27 | 2018-09-19 | Terumo Kabushiki Kaisha | Blood bag and blood bag system provided therewith |
US10159778B2 (en) | 2014-03-24 | 2018-12-25 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US9782707B2 (en) | 2014-03-24 | 2017-10-10 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US9796166B2 (en) | 2014-03-24 | 2017-10-24 | Fenwal, Inc. | Flexible biological fluid filters |
US9968738B2 (en) | 2014-03-24 | 2018-05-15 | Fenwal, Inc. | Biological fluid filters with molded frame and methods for making such filters |
US10376627B2 (en) | 2014-03-24 | 2019-08-13 | Fenwal, Inc. | Flexible biological fluid filters |
US10507165B2 (en) | 2017-05-31 | 2019-12-17 | Adienne Pharma & Biotech Sa | Multi chamber flexible bag and methods of using same |
US10369077B2 (en) | 2017-05-31 | 2019-08-06 | Adienne Pharma & Biotech Sa | Multi chamber flexible bag and methods of using the same |
AU2017424447A1 (en) * | 2017-07-18 | 2020-01-16 | Ahmad GHANBARI | Method, device and kit for the preparation of PRP |
CN110944616A (en) * | 2017-07-22 | 2020-03-31 | 艾哈迈德·甘巴里 | PRP production kit with the ability to separate PRP from blood and then infuse the remaining elements |
CN111548992A (en) * | 2020-05-28 | 2020-08-18 | 章毅 | Method and device for preparing immune cells in blood in large scale |
CN112481098A (en) * | 2020-12-11 | 2021-03-12 | 深圳市北科生物科技有限公司 | Four-in-one bag for separating and storing peripheral blood immune cells and separation method |
Citations (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2702034A (en) * | 1950-07-20 | 1955-02-15 | Fenwal Inc | Apparatus for collecting, storing, and dispensing whole blood |
US3187750A (en) * | 1963-01-15 | 1965-06-08 | Baxter Laboratories Inc | Multiple bag blood storage unit |
US3257072A (en) * | 1963-01-07 | 1966-06-21 | Cryogenic Eng Co | Whole blood storage structure |
US3545671A (en) * | 1967-02-14 | 1970-12-08 | Eugene Ross Lab Inc | Apparatus for and method of collecting,storing,separating and dispensing blood and blood components |
US3911918A (en) * | 1972-04-13 | 1975-10-14 | Ralph D Turner | Blood collection, storage and administering bag |
US4004975A (en) * | 1975-12-30 | 1977-01-25 | The United States Of America As Represented By The Secretary Of The Navy | Method of isolating and cryopreserving human white cells from whole blood |
US4040959A (en) * | 1976-06-22 | 1977-08-09 | Berman Irwin R | Multi-purpose blood bag |
US4131200A (en) * | 1976-07-06 | 1978-12-26 | Union Carbide Corporation | Thermoplastic blood bag |
US4223675A (en) * | 1978-07-24 | 1980-09-23 | Baxter Travenol Laboratories, Inc. | Solution containers such as blood bags and system for preparing same |
US4322298A (en) * | 1981-06-01 | 1982-03-30 | Advanced Blood Component Technology, Inc. | Centrifugal cell separator, and method of use thereof |
US4332122A (en) * | 1978-07-24 | 1982-06-01 | Baxter Travenol Laboratories, Inc. | Method of making and filling liquid-containing sterile packages such as blood bags |
US4343793A (en) * | 1980-03-10 | 1982-08-10 | Max-Planck Gesellschaft Zur Forderung Der Wissenschaften | Process for obtaining intact and viable leucocytes and thrombocytes from blood |
US4396383A (en) * | 1981-11-09 | 1983-08-02 | Baxter Travenol Laboratories, Inc. | Multiple chamber solution container including positive test for homogenous mixture |
US4458811A (en) * | 1983-04-21 | 1984-07-10 | Abbott Laboratories | Compartmented flexible solution container |
US4608043A (en) * | 1984-06-22 | 1986-08-26 | Abbott Laboratories | I.V. fluid storage and mixing system |
US4744907A (en) * | 1987-01-16 | 1988-05-17 | Interferon Sciences, Inc. | Blood cell separation |
US4937194A (en) * | 1986-05-12 | 1990-06-26 | Baxter International Inc. | Method for metering nutrient media to cell culture containers |
US5004681A (en) * | 1987-11-12 | 1991-04-02 | Biocyte Corporation | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
US5089146A (en) * | 1990-02-12 | 1992-02-18 | Miles Inc. | Pre-storage filtration of platelets |
US5104788A (en) * | 1989-06-12 | 1992-04-14 | Miles Inc. | Method of preparing neocytes and gerocytes in a closed system |
US5116315A (en) * | 1989-10-03 | 1992-05-26 | Hemaedics, Inc. | Biological syringe system |
US5118428A (en) * | 1990-11-13 | 1992-06-02 | Quidel | Method to remove red blood cells from whole blood samples |
US5154716A (en) * | 1990-11-06 | 1992-10-13 | Miles Inc. | Bottom blood bag separation system |
US5192553A (en) * | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
US5269946A (en) * | 1991-05-22 | 1993-12-14 | Baxter Healthcare Corporation | Systems and methods for removing undesired matter from blood cells |
US5397479A (en) * | 1993-04-26 | 1995-03-14 | International Remote Imaging Systems, Inc. | Composition and method for enrichment of white blood cells from whole human blood |
US5510102A (en) * | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US5523004A (en) * | 1992-12-04 | 1996-06-04 | Terumo Kabushiki Kaisha | Method for treatment of blood using a blood bag |
US5562836A (en) * | 1994-05-11 | 1996-10-08 | Baxter International Inc. | Method for storing blood in a container having multiple chambers |
US5622867A (en) * | 1994-10-19 | 1997-04-22 | Lifecell Corporation | Prolonged preservation of blood platelets |
US5769839A (en) * | 1994-11-14 | 1998-06-23 | Pall Corporation | Long-term blood components storage system and method |
US5789147A (en) * | 1994-12-05 | 1998-08-04 | New York Blood Center, Inc. | Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood |
US5836934A (en) * | 1995-06-07 | 1998-11-17 | Baxter International Inc. | Closed system and methods for mixing additive solutions while removing undesired matter from blood cells |
US7169547B2 (en) * | 1994-12-05 | 2007-01-30 | New York Blood Center, Inc. | High concentration white blood cells as a therapeutic product |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55129755A (en) | 1979-03-30 | 1980-10-07 | Asahi Chem Ind Co Ltd | Catch and pick-up filter of white corpuscle |
JPS55136955A (en) | 1979-04-13 | 1980-10-25 | Asahi Chem Ind Co Ltd | Filter for catching and gathering leucocyte |
JPS595118A (en) | 1982-06-30 | 1984-01-12 | Asahi Chem Ind Co Ltd | Method for treating blood and apparatus |
AU578554B2 (en) | 1986-01-24 | 1988-10-27 | Japanese Red Cross Society | Centrifugal method of separating blood components |
CH686778A5 (en) | 1987-05-29 | 1996-06-28 | Vifor Medical Ag | Container for separate storage of active compounds and their subsequent mixing. |
US4874690A (en) | 1988-08-26 | 1989-10-17 | Cryopharm Corporation | Lyophilization of red blood cells |
US5100564A (en) | 1990-11-06 | 1992-03-31 | Pall Corporation | Blood collection and processing system |
JP3501207B2 (en) | 1997-12-25 | 2004-03-02 | 三菱自動車工業株式会社 | Failure diagnosis device for fuel evaporative gas treatment system |
-
2001
- 2001-05-15 US US09/855,789 patent/US7169547B2/en not_active Expired - Lifetime
-
2006
- 2006-12-15 US US11/640,138 patent/US20070179424A1/en not_active Abandoned
Patent Citations (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2702034A (en) * | 1950-07-20 | 1955-02-15 | Fenwal Inc | Apparatus for collecting, storing, and dispensing whole blood |
US3257072A (en) * | 1963-01-07 | 1966-06-21 | Cryogenic Eng Co | Whole blood storage structure |
US3187750A (en) * | 1963-01-15 | 1965-06-08 | Baxter Laboratories Inc | Multiple bag blood storage unit |
US3545671A (en) * | 1967-02-14 | 1970-12-08 | Eugene Ross Lab Inc | Apparatus for and method of collecting,storing,separating and dispensing blood and blood components |
US3911918A (en) * | 1972-04-13 | 1975-10-14 | Ralph D Turner | Blood collection, storage and administering bag |
US4004975A (en) * | 1975-12-30 | 1977-01-25 | The United States Of America As Represented By The Secretary Of The Navy | Method of isolating and cryopreserving human white cells from whole blood |
US4040959A (en) * | 1976-06-22 | 1977-08-09 | Berman Irwin R | Multi-purpose blood bag |
US4131200A (en) * | 1976-07-06 | 1978-12-26 | Union Carbide Corporation | Thermoplastic blood bag |
US4223675A (en) * | 1978-07-24 | 1980-09-23 | Baxter Travenol Laboratories, Inc. | Solution containers such as blood bags and system for preparing same |
US4332122A (en) * | 1978-07-24 | 1982-06-01 | Baxter Travenol Laboratories, Inc. | Method of making and filling liquid-containing sterile packages such as blood bags |
US4343793A (en) * | 1980-03-10 | 1982-08-10 | Max-Planck Gesellschaft Zur Forderung Der Wissenschaften | Process for obtaining intact and viable leucocytes and thrombocytes from blood |
US4322298A (en) * | 1981-06-01 | 1982-03-30 | Advanced Blood Component Technology, Inc. | Centrifugal cell separator, and method of use thereof |
US4396383A (en) * | 1981-11-09 | 1983-08-02 | Baxter Travenol Laboratories, Inc. | Multiple chamber solution container including positive test for homogenous mixture |
US4458811A (en) * | 1983-04-21 | 1984-07-10 | Abbott Laboratories | Compartmented flexible solution container |
US4608043A (en) * | 1984-06-22 | 1986-08-26 | Abbott Laboratories | I.V. fluid storage and mixing system |
US4937194A (en) * | 1986-05-12 | 1990-06-26 | Baxter International Inc. | Method for metering nutrient media to cell culture containers |
US4744907A (en) * | 1987-01-16 | 1988-05-17 | Interferon Sciences, Inc. | Blood cell separation |
US5004681A (en) * | 1987-11-12 | 1991-04-02 | Biocyte Corporation | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
US6605275B1 (en) * | 1987-11-12 | 2003-08-12 | Pharmastem Therapeutics, Inc. | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
US5004681B1 (en) * | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
US6569427B1 (en) * | 1987-11-12 | 2003-05-27 | Pharmastem Therapeutics, Inc. | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
US6461645B1 (en) * | 1987-11-12 | 2002-10-08 | Pharmastem Therapeutics, Inc. | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
US5192553A (en) * | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
US5104788A (en) * | 1989-06-12 | 1992-04-14 | Miles Inc. | Method of preparing neocytes and gerocytes in a closed system |
US5116315A (en) * | 1989-10-03 | 1992-05-26 | Hemaedics, Inc. | Biological syringe system |
US5089146A (en) * | 1990-02-12 | 1992-02-18 | Miles Inc. | Pre-storage filtration of platelets |
US5154716A (en) * | 1990-11-06 | 1992-10-13 | Miles Inc. | Bottom blood bag separation system |
US5118428A (en) * | 1990-11-13 | 1992-06-02 | Quidel | Method to remove red blood cells from whole blood samples |
US5269946A (en) * | 1991-05-22 | 1993-12-14 | Baxter Healthcare Corporation | Systems and methods for removing undesired matter from blood cells |
US5523004A (en) * | 1992-12-04 | 1996-06-04 | Terumo Kabushiki Kaisha | Method for treatment of blood using a blood bag |
US5397479A (en) * | 1993-04-26 | 1995-03-14 | International Remote Imaging Systems, Inc. | Composition and method for enrichment of white blood cells from whole human blood |
US5562836A (en) * | 1994-05-11 | 1996-10-08 | Baxter International Inc. | Method for storing blood in a container having multiple chambers |
US5824216A (en) * | 1994-05-11 | 1998-10-20 | Baxter International Inc. | Blood collection container |
US5622867A (en) * | 1994-10-19 | 1997-04-22 | Lifecell Corporation | Prolonged preservation of blood platelets |
US5769839A (en) * | 1994-11-14 | 1998-06-23 | Pall Corporation | Long-term blood components storage system and method |
US6491678B1 (en) * | 1994-12-05 | 2002-12-10 | New York Blood Center, Inc. | Freezer bag |
US5928214A (en) * | 1994-12-05 | 1999-07-27 | New York Blood Center, Inc. | High concentration white cells, a method for agglomeration of the high concentration and a bag set for use in conjunction therewith |
US5789147A (en) * | 1994-12-05 | 1998-08-04 | New York Blood Center, Inc. | Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood |
US7169547B2 (en) * | 1994-12-05 | 2007-01-30 | New York Blood Center, Inc. | High concentration white blood cells as a therapeutic product |
US5510102A (en) * | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US5836934A (en) * | 1995-06-07 | 1998-11-17 | Baxter International Inc. | Closed system and methods for mixing additive solutions while removing undesired matter from blood cells |
Non-Patent Citations (1)
Title |
---|
Montuoro et al., "A technique for isolation of bone marrow cells using hydroxyethyl starch sedimentation agent", Haematologica 76 (Suppl 1 : 7-9 (1991). * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8617539B2 (en) | 2002-04-13 | 2013-12-31 | Allan Mishra | Method of administration of platelet-rich plasma to treat an acute cardiac dysfunction |
US20080248085A1 (en) * | 2002-04-13 | 2008-10-09 | Bioparadox, Llc | Method of tissue vascularization |
US9320762B2 (en) | 2002-04-13 | 2016-04-26 | Allan Mishra | Compositions and minimally invasive methods for treating incomplete tissue repair |
US20080248081A1 (en) * | 2002-04-13 | 2008-10-09 | Bioparadox, Llc | Method of treating chronic dysfunction of cardiac muscle |
US8142993B1 (en) | 2004-08-20 | 2012-03-27 | Allan Mishra | Method of preparing neutrophil-depleted platelet-rich plasma |
US20090092679A1 (en) * | 2004-08-20 | 2009-04-09 | Allan Mishra | Particle/cell separation device and compositions |
US9351999B2 (en) | 2008-10-07 | 2016-05-31 | Bioparadox, Llc | Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities |
US20100112081A1 (en) * | 2008-10-07 | 2010-05-06 | Bioparadox, Llc | Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities |
US11638548B2 (en) | 2008-10-07 | 2023-05-02 | Blue Engine Biologies, LLC | Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities |
US8440459B2 (en) | 2008-10-09 | 2013-05-14 | Allan Kumar Mishra | Platelet rich plasma formulations for cardiac treatments |
US8444969B2 (en) | 2008-10-09 | 2013-05-21 | Allan Mishra | Neutrophil-depleted platelet rich plasma formulations for cardiac treatments |
US20100092444A1 (en) * | 2008-10-09 | 2010-04-15 | Bioparadox, Llc | Platelet rich plasma formulations for cardiac treatments |
US20100233282A1 (en) * | 2009-03-13 | 2010-09-16 | Allan Mishra | Device and methods for delivery of bioactive materials to the right side of the heart |
US20140221958A1 (en) * | 2013-01-31 | 2014-08-07 | Biomet Biologics, Llc | Functionally-closed, sterile blood processing solution system and method |
US9550015B2 (en) | 2013-01-31 | 2017-01-24 | Biomet Biologies, LLC | Functionally-closed, sterile blood processing solution system and method |
US9808487B2 (en) | 2013-01-31 | 2017-11-07 | Biomet Biologics, Llc | Methods for rejuvenating red blood cells |
US9950012B2 (en) | 2013-01-31 | 2018-04-24 | Biomet Biologics, Llc | Methods for rejuvenating red blood cells |
US10898520B2 (en) | 2013-01-31 | 2021-01-26 | Biomet Biologics, Llc | Methods for rejuvinating red blood cells |
US9011408B2 (en) * | 2013-01-31 | 2015-04-21 | Biomet Biologics, Llc | Functionally-closed, sterile blood processing solution system and method |
US10214727B2 (en) | 2013-06-04 | 2019-02-26 | Allan Mishra | Platelet-rich plasma compositions and methods of preparation |
Also Published As
Publication number | Publication date |
---|---|
US20010034513A1 (en) | 2001-10-25 |
US7169547B2 (en) | 2007-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6491678B1 (en) | Freezer bag | |
US7169547B2 (en) | High concentration white blood cells as a therapeutic product | |
Rubinstein et al. | Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. | |
Hogg | Neutrophil kinetics and lung injury | |
AU2014221330B2 (en) | Combined organ and hematopoietic cells for transplantation tolerance of grafts | |
McMichael et al. | Effect of leukoreduction on transfusion‐induced inflammation in dogs | |
US8013022B2 (en) | Stabilized products, process and devices for preparing same | |
AU621553B2 (en) | Improved system | |
US4473552A (en) | Anaerobic method for preserving whole blood, tissue and components containing living mammalian cells | |
WO1998032840A1 (en) | Method for separating cells | |
Tullis et al. | Studies on the in vivo survival of glycerolized and frozen human red blood cells | |
US20150306288A1 (en) | Method for preserving placental blood | |
Huggins | Frozen blood | |
Sputtek | Cryopreservation of red blood cells and platelets | |
Feldman et al. | Modern veterinary blood banking practices and their applications in companion animal practice | |
BCSH Blood Transfusion Task Force et al. | Guidelines for the collection, processing and storage of human bone marrow and peripheral stem cells for transplantation | |
EP0061277B1 (en) | Anaerobic method for preserving whole blood, tissue and components containing living mammalian cells | |
Landi et al. | Effects of high platelet concentration in collecting and freezing dry platelets concentrates | |
Lagerberg | Frozen blood reserves | |
Snyder et al. | Stability of red cell antigens during prolonged storage in citrate‐phosphate‐dextrose and a new preservative solution | |
RU2744614C1 (en) | Method for reducing toxicity of cryopreservation solution based on dimethyl sulfoxide after thawing of hematopoietic stem cells | |
Tullis et al. | Disposable plastic centrifuge bowls for separation of red blood cells and plasma in the processing of frozen blood | |
Dobrila | Cord Blood Processing: Different Bags and Automation | |
Dobrila et al. | EFFECT OF TRANSIENT WARMING EVENTS ON HEMATOPOIETIC PROGENITOR CELL VIABILITY IN CRYOPRESERVED UNITS OF UMBILICAL CORD BLOODS | |
Green | THE ANTIGENIC NATURE OF ERYTHROCYTES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NEW YORK BLOOD CENTER, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RUBINSTEIN, PABLO;COELHO, PHILIP H.;STEVENS, CLADD E.;REEL/FRAME:022187/0525;SIGNING DATES FROM 19951108 TO 19960105 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |